In addition to conventional chemotherapy, targeted therapies targeting epidermal growth factor receptor (EGFR) and receptor tyrosine kinase (ALK), which block mutant targets of lung adenocarcinoma, have become the first‐line treatment of choice.3, 4 At the same time, programmed death ligand‐1 (PD‐L1) plays an important role in tumorigenesis and development, and promotes the wide application of immunotherapy in lung cancer.5, 6. Here, EGFR is linked to lung cancer.